Page 2291 - Williams Hematology ( PDFDrive )

2266 Part XII: Hemostasis and Thrombosis <CN>: <ct> PB

161. Al-Nouri ZL, Reese JA, Terrell DR, et al: Drug-induced thrombotic microangiopathy: 169. Valavaara R, Nordman E: Renal complications of mitomycin C therapy with special
A systematic review of published reports. Blood 125:616, 2015. reference to the total dose. Cancer 55:47, 1985.
162. Schwartz J, Winters JL, Padmanabhan A, et al: Guidelines on the use of therapeutic 170. Lesesne JB, Rothschild N, Erickson B, et al: Cancer-associated hemolytic-uremic syn-
apheresis in clinical practice-evidence-based approach from the Writing Committee of drome: Analysis of 85 cases from a national registry. J Clin Oncol 7:781, 1989.
the American Society for Apheresis: The sixth special issue. J Clin Apher 28:145, 2013. 171. Humphreys BD, Sharman JP, Henderson JM, et al: Gemcitabine-associated thrombotic
163. Kojouri K, Vesely SK, George JN: Quinine-associated thrombotic thrombocytopenic microangiopathy. Cancer 100:2664, 2004.
purpura-hemolytic uremic syndrome: Frequency, clinical features, and long-term out- 172. Glezerman I, Kris MG, Miller V, et al: Gemcitabine nephrotoxicity and hemolytic ure-
comes. Ann Intern Med 135:1047, 2001. mic syndrome: Report of 29 cases from a single institution. Clin Nephrol 71:130, 2009.
164. Dlott JS, Danielson CF, Blue-Hnidy DE, McCarthy LJ: Drug-induced thrombotic 173. Eremina V, Jefferson JA, Kowalewska J, et al: VEGF inhibition and renal thrombotic
thrombocytopenic purpura/hemolytic uremic syndrome: A concise review. Ther Apher microangiopathy. N Engl J Med 358:1129, 2008.
Dial 8:102, 2004. 174. Bollee G, Patey N, Cazajous G, et al: Thrombotic microangiopathy secondary to VEGF
165. Bennett CL, Kim B, Zakarija A, et al: Two mechanistic pathways for thienopyri- pathway inhibition by sunitinib. Nephrol Dial Transplant 24:682, 2009.
dine-associated thrombotic thrombocytopenic purpura: A report from the SERF-TTP 175. Carrillo-Carrasco N, Chandler RJ, Venditti CP: Combined methylmalonic acidemia
Research Group and the RADAR Project. J Am Coll Cardiol 50:1138, 2007. and homocystinuria, cblC type. I. Clinical presentations, diagnosis and management.
166. Remuzzi G, Bertani T: Renal vascular and thrombotic effects of cyclosporine. Am J Inherit Metab Dis 35:91, 2012.
J Kidney Dis 13:261, 1989. 176. van den Born BJ, van der Hoeven NV, Groot E, et al: Association between throm-
167. Bechstein WO: Neurotoxicity of calcineurin inhibitors: Impact and clinical manage- botic microangiopathy and reduced ADAMTS13 activity in malignant hypertension.
ment. Transpl Int 13:313, 2000. Hypertension 51:862, 2008.
168. Scott LJ, McKeage K, Keam SJ, Plosker GL: Tacrolimus: A further update of its use in the
management of organ transplantation. Drugs 63:1247, 2003.

Kaushansky_chapter 132_p2253-2266.indd 2266 17/09/15 3:48 pm